Pangaea Oncology, S.A.
Research Pangaea Oncology, S.A. (PANG.MC) on Bullrun: market cap EUR 51.36M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPANG.MC
- ExchangeMC
- CountrySpain
- SectorHealthcare
- IndustryDiagnostics & Research
- CurrencyEUR
- Market capEUR 51.36M
- Financial periodFY2025
- RevenueEUR 14.52M
- Revenue growth1.8%
- Net income-EUR 3.60M
- Free cash flow-EUR 2.99M
- Gross margin99.3%
Valuation Snapshot
latest market cap is EUR 51.36M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 14.52M | -EUR 3.60M | -EUR 2.99M | 99.3% | n/a | EUR 1.98M | EUR 5.82M | EUR 21.30M |
| FY2024 | EUR 14.27M | -EUR 1.17M | -EUR 5.08M | 100.1% | -0.03 | EUR 3.34M | EUR 5.61M | EUR 22.10M |
| FY2023 | EUR 7.39M | -EUR 4.50M | -EUR 2.69M | 101.0% | -0.15 | EUR 1.38M | EUR 5.39M | EUR 17.98M |
| FY2022 | EUR 4.37M | -EUR 2.71M | -EUR 3.70M | 94.1% | -0.09 | EUR 7.10M | EUR 3.75M | EUR 22.89M |
| FY2021 | n/a | n/a | n/a | n/a | -0.03 | n/a | n/a | n/a |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-04 | EUR 51.36M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About Pangaea Oncology, S.A.
Pangaea Oncology, S.A., a precision oncology company, provides a range of services to cancer patients in Spain and the rest of European Union countries. The company offers molecular diagnostics, including mutation analysis in tissue and liquid biopsy; gene amplification and translocation testing; immunohistochemistry (IHC) and fluorescence in-situ hybridization (FISH); gene expression profiling and transcriptomic signatures;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Pangaea Oncology, S.A.'s market cap?
Pangaea Oncology, S.A.'s market capitalization is EUR 51.36M.
What does Pangaea Oncology, S.A. do?
Pangaea Oncology, S.A., a precision oncology company, provides a range of services to cancer patients in Spain and the rest of European Union countries. The company offers molecular diagnostics, including mutation analysis in tissue and liquid biopsy; gene amplification and translocation testing; immunohistochemistry (IHC) and fluorescence in-situ hybridization (FISH); gene expression profiling and transcriptomic signatures; and tumor mutational burden (TMB) and microsatellite instability and (MSI) assessment services. It also provides diagnostic platforms validation and pre-clinical services.